Atrion (NASDAQ:ATRI) Sees Strong Trading Volume

Atrion Co. (NASDAQ:ATRI) shares saw unusually-strong trading volume on Wednesday . Approximately 13,511 shares were traded during mid-day trading, a decline of 18% from the previous session’s volume of 16,444 shares.The stock last traded at $410.50 and had previously closed at $409.13.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Atrion from a “sell” rating to a “hold” rating in a research report on Friday, March 1st.

Atrion Stock Down 3.3 %

The business’s 50-day simple moving average is $400.65 and its two-hundred day simple moving average is $365.24. The firm has a market cap of $678.83 million, a price-to-earnings ratio of 34.97 and a beta of 0.60.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings data on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. The business had revenue of $43.58 million during the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%.

Atrion Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 29th. Investors of record on Friday, March 15th were given a dividend of $2.20 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $8.80 annualized dividend and a dividend yield of 2.28%. Atrion’s dividend payout ratio (DPR) is presently 79.78%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ATRI. Copeland Capital Management LLC raised its position in shares of Atrion by 56.4% during the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 31 shares during the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Atrion during the 4th quarter worth about $36,000. FMR LLC raised its position in shares of Atrion by 38.0% during the 1st quarter. FMR LLC now owns 69 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 19 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Atrion during the 3rd quarter worth about $60,000. Finally, Advisor Group Holdings Inc. acquired a new position in shares of Atrion during the 4th quarter worth about $65,000. Institutional investors and hedge funds own 66.19% of the company’s stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.